When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
Binet
J L
JL
D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010440:Peptichemio / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012737:Sex Factors; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone